BVS
Bioventus Inc
NASDAQ: BVS · HEALTHCARE · MEDICAL DEVICES
$10.14
+3.91% today
Updated 2026-06-05
Market cap
$589.41M
P/E ratio
21.22
P/S ratio
1.02x
EPS (TTM)
$0.41
Dividend yield
—
52W range
$6 – $11
Volume
0.6M
WallStSmart proprietary scores
51
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C4.5
Quality
C6.0
Profitability
B5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$14.80
+45.96%
12-Month target
$9.16
-9.66%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $8.36M — positive
Risks
- Altman Z 0.90 — distress zone
- Thin margins at 4.94%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $512.12M | $512.35M | $573.28M | $568.09M | $576.30M |
| Net income | $-158.70M | $-156.23M | $-33.54M | $22.73M | $3.11M |
| EPS | — | — | — | — | $0.41 |
| Free cash flow | $-15.02M | $7.98M | $37.79M | $71.41M | $8.36M |
| Profit margin | -30.99% | -30.49% | -5.85% | 4.00% | 4.94% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-10 | SINGLETON, MARK LEONARD | Sale | 13,000 | — |
| 2026-04-10 | SINGLETON, MARK LEONARD | Buy | 13,000 | — |
| 2026-04-10 | SINGLETON, MARK LEONARD | Sale | 5,648 | $9.06 |
Peer comparison
Smart narrative
Bioventus Inc trades at $10.14. representing a P/E of 21.22x trailing earnings. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.90, it sits in the distress. TTM revenue stands at $576.30M. with profit margins at 4.94%.
Frequently asked questions
What is Bioventus Inc's stock price?
Bioventus Inc (BVS) trades at $10.14, on a P/E of 21.2x and a P/S of 1.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Bioventus Inc overvalued?
Bioventus Inc carries a Smart Value Score of 51/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Bioventus Inc (BVS)?
The 12-month analyst consensus target is $14.80, about 46.0% above the current $10.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of BVS by 2030?
Our research-backed model puts the 2030 base case at $13.31, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Bioventus Inc's revenue?
Bioventus Inc's trailing twelve-month revenue is $576.30M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Bioventus Inc's Altman Z-Score is 0.90, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.02x
ROE16.50%
Beta0.67
50D MA$9.67
200D MA$8.10
Shares out0.07B
Float0.03B
Short ratio—
Avg volume0.6M
Performance
1 week+0.00%
1 month-14.56%
3 months+1.92%
YTD+21.51%
1 year—
3 years—
5 years—